Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 10:49 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 303 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Forest Laboratories Clear all
Completed Phase 4 Interventional Results available

Memantine and Cognitive Dysfunction in Bipolar Disorder

NCT00586066
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Memantine, Placebo
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
3
States / cities
Los Angeles, California • Chicago, Illinois • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 6, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Cariprazine (RGH-188) in the Acute Exacerbation of Schizophrenia

NCT00694707
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine, Risperidone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
732 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
18
States / cities
Costa Mesa, California • Long Beach, California • Oceanside, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Brain Effects of Escitalopram and Citalopram Using fMRI

NCT00825825
View directory record Official record
Conditions
Antidepressant Activity in Healthy Volunteers
Interventions
Escitalopram, Citalopram, Placebo
Drug
Lead sponsor
Michael Henry, MD
Other
Eligibility
21 Years to 50 Years · Male only
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2011
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 14, 2015 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Memantine Treatment in Fragile X-Associated Tremor/Ataxia Syndrome

NCT00584948
View directory record Official record
Conditions
Fragile X-Associated Tremor/Ataxia Syndrome, Fragile X Premutation Carriers
Interventions
Memantine, Placebo
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
30 Years to 80 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
2
States / cities
Sacramento, California • Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Discontinuation Study of the Durability of Effect of Milnacipran for the Treatment of Fibromyalgia

NCT01014585
View directory record Official record
Conditions
Fibromyalgia
Interventions
Placebo, Milnacipran
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
Not listed
Enrollment
340 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
58
States / cities
Birmingham, Alabama • Tucson, Arizona • Fresno, California + 51 more
Source: ClinicalTrials.gov public record
Updated Sep 7, 2011 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Dutogliptin/PHX1149T to Treat Type 2 Diabetes Mellitus

NCT00690638
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
PHX1149T, Placebo
Drug
Lead sponsor
Phenomix
Industry
Eligibility
18 Years to 85 Years
Enrollment
480 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
13
States / cities
Norwalk, California • Orange, California • Santa Ana, California + 10 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2010 · Synced Oct 3, 2026, 10:49 PM EDT
Withdrawn Phase 4 Interventional

Ceftaroline in the Treatment of Bone and Joint Infections

NCT02005068
View directory record Official record
Conditions
Osteomyelitis, Joint Infections
Interventions
Ceftaroline
Drug
Lead sponsor
Orlando Health, Inc.
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 7, 2014 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional

Escitalopram for the Treatment of Self-Injurious Skin Picking

NCT00115011
View directory record Official record
Conditions
Impulse Control Disorders
Interventions
Escitalopram
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 20, 2008 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 4 Interventional

Namenda to Prevent Post-Operative Delirium

NCT00303433
View directory record Official record
Conditions
Delirium, Post-Operative States
Interventions
Namenda
Drug
Lead sponsor
University of Rochester
Other
Eligibility
50 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jun 3, 2015 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Not applicable Interventional Results available

Does Memantine Improve Verbal Memory Task Performance in Subjects With Partial Epilepsy and Memory Dysfunction?

NCT01054599
View directory record Official record
Conditions
Epilepsy
Interventions
Memantine, Sugar Pill
Drug · Other
Lead sponsor
American Academy of Neurology
Other
Eligibility
18 Years to 65 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts • Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

An Open-Label, Long-Term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

NCT00765999
View directory record Official record
Conditions
Chronic Constipation, Irritable Bowel Syndrome With Constipation
Interventions
Linaclotide
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years and older
Enrollment
1,559 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
110
States / cities
Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 94 more
Source: ClinicalTrials.gov public record
Updated Feb 15, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional

"MILNACIPRAN" in Subjects With Chronic Shoulder Pain

NCT01289236
View directory record Official record
Conditions
Chronic Shoulder Pain
Interventions
Milnacipran, Placebo
Drug
Lead sponsor
Valera Bussell
Industry
Eligibility
25 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Delray Beach, Florida
Source: ClinicalTrials.gov public record
Updated Aug 9, 2012 · Synced Oct 3, 2026, 10:49 PM EDT
Withdrawn Phase 3 Interventional

Pain Assessment and Quality of Life in Back Pain Patients: Role of Milnacipran

NCT01221740
View directory record Official record
Conditions
Back Pain
Interventions
Savella
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Chestnut Hill, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 4 Interventional Results available

Lexapro for Major Depression in Patients With Epilepsy

NCT01244724
View directory record Official record
Conditions
Major Depression, Epilepsy
Interventions
Lexapro
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Safety and Efficacy of Cariprazine in Schizophrenia

NCT01104779
View directory record Official record
Conditions
Schizophrenia
Interventions
Cariprazine, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
446 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
15
States / cities
Costa Mesa, California • Long Beach, California • Paramount, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Oct 3, 2026, 10:49 PM EDT
Terminated Phase 2 Interventional Results available

Safety Study of Memantine in Pediatric Patients With Autism, Asperger's Disorder or Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)

NCT01592773
View directory record Official record
Conditions
Autism Spectrum Disorder (ASD), Autism, Autistic Disorder, Asperger's Disorder, Asperger's, Pediatric Autism, Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS)
Interventions
Memantine Hydrochloride (HCl)
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
6 Years to 12 Years
Enrollment
747 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
68
States / cities
Dothan, Alabama • Phoenix, Arizona • Tucson, Arizona + 62 more
Source: ClinicalTrials.gov public record
Updated Feb 16, 2015 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 1 Interventional

Effects of Milnacipran on Widespread Mechanical and Thermal Hyperalgesia of Fibromyalgia Patients

NCT01294059
View directory record Official record
Conditions
Fibromyalgia
Interventions
Milnacipran
Drug
Lead sponsor
University of Florida
Other
Eligibility
30 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

Safety, Efficacy and Tolerability of Vilazodone in Generalized Anxiety Disorder

NCT01629966
View directory record Official record
Conditions
Generalized Anxiety Disorder
Interventions
Placebo, Vilazodone
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 70 Years
Enrollment
680 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
37
States / cities
Birmingham, Alabama • Beverly Hills, California • Glendale, California + 31 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2019 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

A Study on the Efficacy and Safety of Nebivolol Monotherapy in Hispanic Hypertensive Patients

NCT00770861
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol, Placebo
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
277 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
29
States / cities
Buena Park, California • Chino, California • Long Beach, California + 19 more
Source: ClinicalTrials.gov public record
Updated Jan 26, 2011 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

A Randomized, Clinical Trial of Vitamin E and Memantine in Alzheimer's Disease

NCT00235716
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
dl-alpha-tocopherol, Memantine, Placebo
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
40 Years and older
Enrollment
613 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
13
States / cities
Bay Pines, Florida • Miami, Florida • Iowa City, Iowa + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 23, 2014 · Synced Oct 3, 2026, 10:49 PM EDT
Withdrawn Phase 2Phase 3 Interventional

Safety Study of Nebivolol for COPD Patients

NCT01939990
View directory record Official record
Conditions
High Blood Pressure
Interventions
Placebo, Nebivolol
Drug
Lead sponsor
University of Chicago
Other
Eligibility
40 Years to 75 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 12, 2016 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Effect of Nebivolol on the Blood Flow in Hearts of Adults With High Blood Pressure and Abnormal Filling of Heart

NCT01961323
View directory record Official record
Conditions
Hypertension, Left Ventricular Diastolic Dysfunction
Interventions
Nebivolol
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 3 Interventional Results available

A Study of Cariprazine in the Prevention of Relapse of Symptoms in Participants With Schizophrenia

NCT01412060
View directory record Official record
Conditions
Schizophrenia
Interventions
Placebo, Cariprazine
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 60 Years
Enrollment
765 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
25
States / cities
Little Rock, Arkansas • Cerritos, California • Costa Mesa, California + 20 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2018 · Synced Oct 3, 2026, 10:49 PM EDT
Completed Phase 4 Interventional Results available

Treatment of Outpatients With Severe Asthma and Moderate or Severe Major Depressive Disorder

NCT00621946
View directory record Official record
Conditions
Severe Asthma, Moderate or Severe Major Depressive Disorder
Interventions
Placebo, Escitalopram
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Feb 4, 2014 · Synced Oct 3, 2026, 10:49 PM EDT